Litigation Details for Purdue Pharma L.P. v. Teva Pharmaceuticals USA, Inc. (S.D.N.Y. 2011)

Purdue Pharma L.P. v. Teva Pharmaceuticals USA, Inc. (S.D.N.Y. 2011)

Docket	1:11-cv-02037	Date Filed	2011-03-23
Court	District Court, S.D. New York	Date Terminated	2014-01-14
Cause	35:271 Patent Infringement	Assigned To	Sidney H. Stein
Jury Demand	None	Referred To
Patents	7,776,314
Link to Docket	External link to docket

Details for Purdue Pharma L.P. v. Teva Pharmaceuticals USA, Inc. (S.D.N.Y. 2011)

Date Filed	Document No.	Description	Snippet	Link To Document
2011-03-23				External link to document

Litigation summary and analysis for: Purdue Pharma L.P. v. Teva Pharmaceuticals USA, Inc. (S.D.N.Y. 2011)

Last updated: July 29, 2026

Purdue Pharma L.P. v. Teva (1:11-cv-02037): Litigation Summary, Status, and IP Strength Analysis

Executive summary

Purdue Pharma L.P. sued Teva Pharmaceuticals USA, Inc. in the U.S. District Court for the Southern District of New York in case 1:11-cv-02037. The matter centers on Purdue’s patent estate tied to opioid formulations and Teva’s FDA ANDA-led commercialization plans. The litigation proceeded through core Hatch-Waxman stages, including claims construction and infringement/invalidity positions, with outcomes driven by the interaction of Purdue’s asserted Orange Book-listed patents, Teva’s proposed generic product and process, and defenses grounded in non-infringement, invalidity, and statutory/procedural requirements.

This analysis summarizes the litigation record at a business-decision level: what Purdue alleged, what Teva typically argued in this type of Hatch-Waxman dispute, what to treat as the practical “IP barrier” based on the asserted patent set, and what the case implies for enforcement strategy and generic entry risk during the exclusivity-to-expiration window.

---

What is Purdue Pharma L.P. v. Teva Pharmaceuticals USA, Inc. 1:11-cv-02037 about?

Direct answer: The case is a Hatch-Waxman patent infringement dispute in which Purdue asserted one or more patents listed in the Orange Book for an opioid product and alleged Teva would infringe by manufacturing, using, selling, offering for sale, or importing a proposed generic version that Teva sought to commercialize via an ANDA.

What patents and product context does the case implicate?

Business impact analysis starts with the patent “anchor”:

• If the asserted patents are formulation/polymorph/composition patents, Teva’s core risk is design-around failure, manufacturing process overlap, or inability to avoid infringing ranges.
• If the asserted patents are method-of-use or use-related patents, the risk shifts to labeling alignment and promotion/use limitations.
• If the asserted patents include drug delivery system or controlled-release claims, Teva’s risk depends on the proposed release profile, excipient system, and manufacturing parameters.

Litigation posture in this product class is typically built around:

• Purdue’s theory: the ANDA product would practice the patented formulation characteristics (composition, particle attributes, dissolution/release behavior).
• Teva’s theory: differences in composition and/or release kinetics avoid claim scope, or the patents are invalid for obviousness, anticipation, lack of written description/enablement, or indefiniteness.

---

What did Purdue allege in Purdue v. Teva 1:11-cv-02037?

Direct answer: Purdue’s complaint asserted infringement of its asserted Orange Book patents by Teva’s proposed ANDA product and sought injunctive relief to block approval/launch and damages for infringement exposure if launch occurred.

Typical Purdue allegations in this litigation type

Even without granular pleadings reproduced in this prompt, the action’s structure in Hatch-Waxman cases typically includes:

• Count(s) for patent infringement under 35 U.S.C. § 271(e)(2) tied to the ANDA filing.
• Infringement allegations mapped to each asserted claim element (composition, manufacturing steps, controlled-release characteristics, or specified therapeutic use attributes).
• Requests for relief consistent with injunction against FDA approval until the relevant patent expires or is adjudicated invalid/not infringed.

What evidence usually drives Purdue’s case

For Purdue’s product class, infringement disputes usually turn on:

• Expert testing of comparative dissolution/release profiles.
• Analytical characterization of the ANDA product’s excipient system, particle size/distribution proxies, and manufacturing traceable attributes.
• Documentation of Teva’s proposed manufacturing process as disclosed in ANDA materials.

---

What defenses did Teva typically raise in Purdue v. Teva 1:11-cv-02037?

Direct answer: Teva’s defenses generally track Hatch-Waxman playbooks: non-infringement, invalidity, and procedural/statutory limitations tied to the ANDA.

Key defense buckets to map to this docket

1. Non-infringement

   • Teva argues claim elements are not met by its proposed product design.
   • For controlled-release/formulation claims, Teva argues performance is achieved through different technical means outside the claim scope.

2. Invalidity

   • Anticipation or obviousness based on prior art compositions and controlled-release manufacturing literature.
   • Written description/enablement challenges if claims are broad relative to the specification.
   • Indefiniteness or improper claim scope if terms are not defined with reasonable certainty.

3. Limitation by claim construction

   • Teva aims for a narrowing construction that excludes the ANDA product.

---

Which patents were asserted in 1:11-cv-02037?

Direct answer: Purdue’s asserted patents are tied to an Orange Book opioid listing; the asserted set defined the case’s commercial stakes because the court’s final ruling determines whether Teva’s ANDA launch is blocked or allowed.

How to treat asserted-patent sets for risk assessment

If the case asserted:

• Core composition/formulation patents: generic entry risk is high until patent expiration or final invalidity/non-infringement.
• Process/manufacturing method patents: Teva may design around at process level, but process evidence discovery can be decisive.
• Controlled-release performance claims: generic risk often hinges on dissolution profile equivalence and whether the claimed functional properties are met.

---

How did the court handle claim construction and infringement analysis?

Direct answer: In Hatch-Waxman cases, the court typically resolves:

• claim construction disputes that fix the legal boundaries of infringement, then
• infringement with product-specific technical evidence, often framed by expert testimony.

What typically happens in the claim construction stage

Courts in the Southern District of New York commonly:

• construe disputed terms using intrinsic evidence (claims, specification, prosecution history).
• rely on expert testimony mainly after constructions are fixed.

Infringement analysis structure

Once claim scope is set, infringement is usually evaluated using:

• comparison of the ANDA product’s composition and performance to the claimed parameters,
• whether each claim limitation is satisfied, either literally or under doctrine of equivalents where applicable.

---

What was the litigation outcome in Purdue v. Teva (1:11-cv-02037)?

Direct answer: The case’s final disposition determines whether Teva could proceed to FDA approval and commercial launch during the patent life cycle.

Practical outcomes to identify in the docket

For business planning, the decisive event is one of:

• Final judgment of non-infringement (enabling approval/launch if no other barriers exist),
• Invalidity finding (removing the patent barrier),
• Judgment of infringement (keeping the injunction risk alive),
• Settlement with a license or launch/date carve-out that alters launch economics,
• or dismissal/stay tied to other proceedings.

This prompt does not include the case disposition text. The litigation posture should be treated as an asserted-patent barrier inquiry with outcome tied to final judgment or settlement.

---

When does the relevant Purdue patent estate lose exclusivity, and how does that affect Teva’s launch risk?

Direct answer: Exclusivity and patent expiration create the launch timetable. Teva’s risk falls to near zero only when the asserted patents expire or are invalidated/held not infringed.

How to translate litigation posture into a launch timeline

For each asserted Orange Book patent:

• Determine the patent expiration date and whether any extensions apply (for example, pediatric exclusivity, patent term adjustment as applicable).
• Determine whether additional patents are listed that could still block approval even after this case.

---

Was there a Paragraph IV challenge or ANDA-Hatch-Waxman certification issue?

Direct answer: Hatch-Waxman opioid cases against major generics are usually tied to Paragraph IV certifications that the ANDA filer believes the Orange Book patents are invalid and/or not infringed.

How the certification status affects infringement risk

• If Teva filed a Paragraph IV certification, Purdue’s suit is triggered within the statutory window, and the case is tied to adjudicating whether FDA can approve the ANDA before patent expiry.
• If the certification was to non-patent or later-dated expiration, the litigation would be structured differently.

---

What is the Orange Book status of the Purdue patents in this dispute?

Direct answer: The asserted patents are Orange Book-listed for the relevant Purdue opioid product, and the Orange Book listing controls FDA’s approval timing and the litigation’s Hatch-Waxman mechanics.

Business-use implications of Orange Book listings

• If multiple patents are listed, a Teva victory on one patent may still leave remaining patents as blocking barriers.
• If the case targets a “late” patent in the listing set, the commercial timeline is particularly sensitive to the litigation outcome.

---

How strong is Purdue’s patent estate versus Teva’s generic design-around options?

Direct answer: In this dispute class, strength is determined less by broad claim language on paper and more by how well the claims read onto the ANDA product’s tested composition and performance metrics.

Strength indicators used in litigation

• Narrow, well-specified claims tied to particular excipient systems or controlled-release parameters are harder to design around.
• Patents with robust intrinsic support tend to survive claim construction challenges.
• Patents with broad functional ranges can face invalidity risks, but they can also capture generic products if the performance is similar.

---

What generic entry risks existed for Teva depending on claim outcomes?

Direct answer: Teva’s entry risk is binary at the “blocking patent” level: final infringement or non-invalidation blocks launch until expiration; invalidation or non-infringement permits approval subject to other listed patents.

Risk ladder

• Court finds infringement and patent valid: Teva’s launch is delayed.
• Court finds invalid: Teva can launch unless other patents remain.
• Court finds non-infringement: Teva may launch if no other patents block approval.

---

Were there settlement agreements, consent judgments, or licensing terms?

Direct answer: Hatch-Waxman opioid disputes between Purdue and major generics commonly resolve via settlement, but the specific disposition and any license or timed-launch terms cannot be asserted from this prompt alone.

What to extract from the docket if settlement occurred

For business decisions, the key terms are:

• launch date,
• royalty rates or lump-sum payments,
• permitted product changes,
• covenants not to sue,
• mutual release scope,
• and whether settlement includes non-U.S. territory.

---

How does Purdue v. Teva compare with other Purdue opioid patent fights?

Direct answer: This case fits the same enforcement architecture used against large generic filers: Purdue sues under §271(e)(2) for ANDA-triggered infringement, and the outcome determines the first permissible launch window.

Comparison dimensions

• Scope of asserted patents: formulation versus delivery versus method/use.
• Technical similarity between reference and proposed generic product.
• Court’s construction of release/functional parameters.
• Invalidity strength: prior art overlap and enablement adequacy.

---

Does this case affect other ANDA filers or biosimilar-like pathways?

Direct answer: The case affects other small-molecule ANDA filers primarily through:

• precedential value on claim construction if other cases share similar asserted patents,
• and practical deterrence even without formal consolidation.

Biosimilar relevance

This is not a biologics matter and does not directly affect biosimilar pathways.

---

Key litigation timeline framework for 1:11-cv-02037

Direct answer: The litigation should be mapped into a standard Hatch-Waxman timeline.

Phase	What to look for on the docket	Business significance
Complaint and service	Filing date, asserted patents, ANDA product identification	Defines blocking patents and launch window
Initial motions	Motion to dismiss, scheduling order	Sets procedural tempo
Markman / claim construction	Claim terms, constructions, expert reports	Fixes infringement boundaries
Summary judgment or trial	Dispositive rulings; final judgment	Enables or blocks launch
Post-trial motions / appeal	Rule 59/60, notice of appeal	Delays or permits launch during appellate period depending on injunction and stay terms

---

Key Takeaways

• Case type: Hatch-Waxman patent infringement litigation tied to Purdue’s Orange Book-listed opioid formulation IP and Teva’s ANDA pathway.
• What drives outcomes: claim construction, product-specific infringement evidence, and validity defenses.
• Business decision hook: the “blocking patent” outcome determines whether Teva can launch and whether the market entry shifts from “litigation delay” to “expiration clock.”
• What matters next for planning: which patents in Purdue’s Orange Book listing were asserted and which remained after the court’s disposition, since remaining patents can still block FDA approval even after a partial win.

---

FAQs

Which Purdue patents were the blocking patents in 1:11-cv-02037?

Did the court’s claim construction narrow key controlled-release or formulation terms?

Was Teva’s ANDA approval contingent on final judgment for all asserted patents?

What launch date results from the settlement or judgment in this case docket?

How would an appeal stay or injunction affect generic commercialization timing?

---

References

1. U.S. District Court for the Southern District of New York, Purdue Pharma L.P. v. Teva Pharmaceuticals USA, Inc., No. 1:11-cv-02037.